T Filardi1, V Carnevale2, R Massoud3, C Russo3, L Nieddu4, F Tavaglione1, I Turinese5, A Lenzi1, E Romagnoli1, S Morano6. 1. Department of Experimental Medicine, Policlinico Umberto I, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. 2. Unit of Internal Medicine, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy. 3. Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy. 4. Faculty of Economics, UNINT University, Rome, Italy. 5. Department of Public Health and Infectious Diseases, "Sapienza" University, Rome, Italy. 6. Department of Experimental Medicine, Policlinico Umberto I, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. susanna.morano@uniroma1.it.
Abstract
PURPOSE: Patients with type 2 diabetes (T2DM) have increased fracture risk. Osteopontin (OPN) is a protein involved in bone remodeling and inflammation. The aim of this study was to evaluate the association of OPN with fracture prevalence and with metabolic parameters in post-menopausal women with T2DM. METHODS: Sixty-four post-menopausal women with T2DM (age 67.0 ± 7.8 years, diabetes duration 8.9 ± 6.7 years), enrolled in a previous study, were followed up (3.6 ± 0.9 years). Previous fragility fractures were recorded. The FRAX score (without BMD) was calculated and biochemical parameters (plasma glucose, HbA1c, lipid profile and renal function) were assessed. Serum 25OH-vitamin D, calcium, PTH and OPN were evaluated at baseline. The association between OPN and fracture prevalence at baseline was evaluated by a logistic model. RESULTS: OPN levels were higher in patients with previous fractures (n.25) than in patients without previous fractures at baseline (n.39) (p = 0.006). The odds of having fractures at baseline increased by 6.7 (1.9-31.4, 95% CI, p = 0.007) for each increase of 1 ng/ml in OPN levels, after adjustment for vitamin D and HbA1c levels. Fracture incidence was 4.7%. Higher OPN associated with a decrease in HDL-cholesterol (p = 0.048), after adjustment for age, basal HDL-cholesterol, basal and follow-up HbA1c and follow-up duration. 25OH-vitamin D associated with an increase in FRAX-estimated probability of hip fracture at follow-up (p = 0.029), after adjustment for age, 25OH-vitamin D and time. CONCLUSIONS: In post-menopausal women with T2DM, OPN might be a useful marker of fracture and worse lipid profile.
PURPOSE:Patients with type 2 diabetes (T2DM) have increased fracture risk. Osteopontin (OPN) is a protein involved in bone remodeling and inflammation. The aim of this study was to evaluate the association of OPN with fracture prevalence and with metabolic parameters in post-menopausal women with T2DM. METHODS: Sixty-four post-menopausal women with T2DM (age 67.0 ± 7.8 years, diabetes duration 8.9 ± 6.7 years), enrolled in a previous study, were followed up (3.6 ± 0.9 years). Previous fragility fractures were recorded. The FRAX score (without BMD) was calculated and biochemical parameters (plasma glucose, HbA1c, lipid profile and renal function) were assessed. Serum 25OH-vitamin D, calcium, PTH and OPN were evaluated at baseline. The association between OPN and fracture prevalence at baseline was evaluated by a logistic model. RESULTS:OPN levels were higher in patients with previous fractures (n.25) than in patients without previous fractures at baseline (n.39) (p = 0.006). The odds of having fractures at baseline increased by 6.7 (1.9-31.4, 95% CI, p = 0.007) for each increase of 1 ng/ml in OPN levels, after adjustment for vitamin D and HbA1c levels. Fracture incidence was 4.7%. Higher OPN associated with a decrease in HDL-cholesterol (p = 0.048), after adjustment for age, basal HDL-cholesterol, basal and follow-up HbA1c and follow-up duration. 25OH-vitamin D associated with an increase in FRAX-estimated probability of hip fracture at follow-up (p = 0.029), after adjustment for age, 25OH-vitamin D and time. CONCLUSIONS: In post-menopausal women with T2DM, OPN might be a useful marker of fracture and worse lipid profile.
Authors: Lora M Giangregorio; William D Leslie; Lisa M Lix; Helena Johansson; Anders Oden; Eugene McCloskey; John A Kanis Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741
Authors: Alexandra Kautzky-Willer; Majid Reza Kamyar; Dora Gerhat; Ammon Handisurya; Gunar Stemer; Stephen Hudson; Anton Luger; Rosa Lemmens-Gruber Journal: Gend Med Date: 2010-12
Authors: Joep van der Leeuw; Joline W J Beulens; Susan van Dieren; Casper G Schalkwijk; Jan F C Glatz; Marten H Hofker; W M Monique Verschuren; Jolanda M A Boer; Yolanda van der Graaf; Frank L J Visseren; Linda M Peelen; Yvonne T van der Schouw Journal: J Am Heart Assoc Date: 2016-05-31 Impact factor: 5.501
Authors: P Borsky; Z Fiala; C Andrys; M Beranek; K Hamakova; J Kremlacek; A Malkova; T Svadlakova; J Krejsek; V Palicka; V Rehacek; L Kotingova; L Borska Journal: Physiol Res Date: 2021-05-12 Impact factor: 1.881